| |
Pre vs 1 cycle
|
Pre vs 9 cycles
|
|---|
|
Subset
|
Increase
|
Minimal change
|
Decrease
|
P-value
|
Increase
|
Minimal change
|
Decrease
|
P-value
|
|---|
|
A. Classic subsets
|
|
CD4
|
0 (0%)
|
18 (95%)
|
1 (5%)
|
0.0230 (↑^, 0.2070)
|
0 (0%)
|
12 (75%)
|
4 (25%)
|
0.0063 (↓^, 0.0567)
|
|
CD8
|
1 (5%)
|
16 (84%)
|
2 (11%)
|
0.1447 (=)
|
3 (19%)
|
11 (68%)
|
2 (13%)
|
0.9799 (=)
|
|
Tregs
|
7 (37%)
|
10 (53%)
|
2 (10%)
|
0.2253 (=)
|
2 (12%)
|
7 (44%)
|
7 (44%)
|
0.0934 (=)
|
|
NK
|
5 (26%)
|
10 (53%)
|
4 (21%)
|
0.8288 (=)
|
0 (0%)
|
9 (56%)
|
7 (44%)
|
0.0182 (↓^, 0.1456)
|
|
NK-T
|
2 (11%)
|
15 (78%)
|
2 (11%)
|
0.2413 (=)
|
1 (6%)
|
12 (75%)
|
3 (19%)
|
0.1046 (=)
|
|
B cells
|
5 (26%)
|
12 (63%)
|
2 (11%)
|
0.7381 (=)
|
6 (38%)
|
5 (31%)
|
5 (31%)
|
0.8209 (=)
|
|
cDC
|
3 (16%)
|
15 (79%)
|
1 (5%)
|
0.3955 (=)
|
6 (37%)
|
7 (44%)
|
3 (19%)
|
0.7436 (=)
|
|
pDC
|
6 (32%)
|
8 (42%)
|
5 (26%)
|
0.4900 (=)
|
6 (38%)
|
9 (56%)
|
1 (6%)
|
0.0833 (=)
|
|
MDSC
|
8 (42%)
|
8 (42%)
|
3 (16%)
|
0.1232 (=)
|
8 (50%)
|
7 (44%)
|
1 (6%)
|
0.0833 (=)
|
|
B. PD-L1+ classic subsets
|
|
PD-L1+ CD4
|
5 (26%)
|
9 (48%)
|
5 (26%)
|
0.9843 (=)
|
3 (19%)
|
9 (56%)
|
4 (25%)
|
0.9999 (=)
|
|
PD-L1+ CD8
|
4 (21%)
|
9 (47%)
|
6 (32%)
|
0.1688 (=)
|
4 (25%)
|
9 (56%)
|
3 (19%)
|
0.9999 (=)
|
|
PD-L1+ Treg
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
|
PD-L1+ NK
|
5 (26%)
|
6 (32%)
|
8 (42%)
|
0.4180 (=)
|
7 (44%)
|
7 (44%)
|
2 (12%)
|
0.1046 (=)
|
|
PD-L1+ NK-T
|
5 (26%)
|
8 (42%)
|
6 (32%)
|
0.4900 (=)
|
6 (38%)
|
6 (38%)
|
4 (24%)
|
0.1439 (=)
|
|
PD-L1+ B cells
|
9 (47%)
|
6 (32%)
|
4 (21%)
|
0.6507 (=)
|
6 (37%)
|
7 (44%)
|
3 (19%)
|
0.5282 (=)
|
|
PD-L1+cDC
|
5 (26%)
|
8 (42%)
|
6 (32%)
|
0.3736 (=)
|
2 (13%)
|
4 (25%)
|
10 (62%)
|
0.0386 (↓*, 0.0772)
|
|
PD-L1+ pDC
|
3 (16%)
|
2 (10%)
|
14 (74%)
|
0.0258 (↓*, 0.0774)
|
10 (63%)
|
1 (6%)
|
5 (31%)
|
0.0443 (↑, 0.1005)
|
|
PD-L1+ MDSC
|
8 (42%)
|
6 (32%)
|
5 (26%)
|
0.6507 (=)
|
10 (63%)
|
4 (25%)
|
2 (12%)
|
0.0131 (↑, 0.1703)
|
- Classic subsets (A) and PD-L1+ classic subsets (B) were examined pre-therapy and post-1 cycle (n = 19) and 9 cycles (n = 16) of avelumab. Results are displayed as the number of patients (percentage of total patients) with an increase of more than 25%, minimal change of less than 25%, and a decrease of more than 25% compared to pre-therapy. Unadjusted p-values (= indicates no change; arrows indicate direction of change compared to pre-therapy; and Holm adjusted p-value is listed for subsets with significant unadjusted p-value) were calculated using the Wilcoxon matched-pairs signed rank test. n/a = not applicable as frequency of subset <0.01% PBMC; ^ = majority of patients with minimal change; * = difference in medians pre- vs post-therapy < 0.01
-
cDC conventional dendritic cells, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PBMC peripheral blood mononuclear cell, Tregs regulatory T cells
